Yubin Kang, MD, Oncology, Durham, NC, Duke University Hospital

YubinKangMD

Oncology Durham, NC

Hematologic Oncology

Professor, Medicine, Duke University Medical Center

Dr. Kang is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kang's full profile

Already have an account?

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Hematology/Oncology, 2007 - 2010
  • University of Iowa Hospitals and Clinics
    University of Iowa Hospitals and ClinicsResidency, Internal Medicine, 2005 - 2007
  • St Luke's HospitalInternship, Internal Medicine, 2004 - 2005
  • The Second Military Medicine UnivClass of 1985

Certifications & Licensure

  • SC State Medical License
    SC State Medical License 2010 - 2023
  • NC State Medical License
    NC State Medical License 2007 - 2021
  • IA State Medical License
    IA State Medical License 2005 - 2007
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
    Yubin Kang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
    Yubin Kang, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • OncLive® Presents State of the Science Summit™ on Hematologic Malignancies
    OncLive® Presents State of the Science Summit™ on Hematologic MalignanciesApril 25th, 2019
  • RedHill Biopharma Announces Presentation on YELIVA® (Opaganib) for Multiple Myeloma at EORTC-NCI-AACR Symposium
    RedHill Biopharma Announces Presentation on YELIVA® (Opaganib) for Multiple Myeloma at EORTC-NCI-AACR SymposiumNovember 14th, 2018

Hospital Affiliations